Implications of IDH mutations on immunotherapeutic strategies for malignant glioma
Immunotherapy has emerged as a promising approach for treating aggressive solid tumors, even within the CNS. Mutation in the metabolic gene isocitrate dehydrogenase 1 (IDH1) represents not only a major glioma defining biomarker but also an attractive therapeutic neoantigen. As patients with IDH-muta...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association of Neurological Surgeons
2022
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |